Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Celestica Inc (CLS) Price & Performance

AbCellera Biologics IncTrade
Celestica IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Celestica Inc — how do they compare? AbCellera Biologics Inc trades at $10.3 (market cap $2.99B), while Celestica Inc trades at $337.55 (market cap $39.16B). The key difference: Celestica Inc is far larger — about 13.1× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Celestica Inc nearer its low. Which is the better fit depends on your goals.

ABCLCLS
Market Cap
$2.99B$39.16B
Sector
HealthTechnology
52-Week High
$9.76$472.40
52-Week Low
$2.78$181.34
Enterprise Value
$2.58B$39.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Celestica Inc

CLS trades at $336.97, up 7.11% on the day, with a bearish technical signal from moving averages but strong fundamental performance. The company reported three consecutive quarterly EPS beats, with Q2 2026 actual EPS of $2.54 exceeding the $2.29 estimate. Revenue for 2025 was $12.39 billion, with a net income margin of 7.16% and robust ROE of 52.69%. Recent news highlights a $3 billion equity offering to fund AI infrastructure growth, alongside new contracts with key tech partners.

The outlook is supported by accelerating AI-driven demand and raised guidance, but near-term dilution from the equity raise poses a risk. Analyst consensus is strongly bullish with a $466.50 price target, though the stock's premium valuation requires careful monitoring of execution against growth expectations.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Celestica Inc

Celestica provides supply chain and manufacturing solutions for global technology companies. It specializes in high-complexity assembly and platform solutions for AI data centers, aerospace, and medical markets.

Read more on CLS